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Role of HSD11B2 polymorphisms in essential hypertension and
the diuretic response to thiazides.
Background. The renal 11beta-hydroxysteroid dehydroge-
nase type 2 (11beta HSD2) enzyme inactivates 11-hydroxy
steroids in the kidney, thereby protecting the nonselective min-
eralocorticoid (MR) receptor from occupation by glucocorti-
coids. Loss-of-function mutations in the gene encoding 11beta
HSD2 (HSD11B2) result in overstimulation of the MR and
cause salt-sensitive hypertension.
Methods. We have investigated the role of HSD11B2 in hy-
pertension in 377 genetically homogeneous essential hyperten-
sives from North Sardinia.
Results. Thirty of these patients displayed increased uri-
nary cortisol metabolite ratios (greater than or equal to
2) (tetrahydrocortisol [THF]+allotetrahydrocortisol [aTHF]/
tetrahydrocortisone [THE]) reflecting a mild reduction in
11beta HSD2 activity. No mutations in HSD11B2 were detected
in these patients. All 377 patients were genotyped for a CA
repeat microsatellite in intron 1 of HSD11B2 and a G534A
polymorphism in exon 3 of HSD11B2. CA repeat length was
associated with the (THF+aTHF)/THE ratio, which in turn was
significantly related to PRA levels. No associations were found
between the G354A polymorphism and the other parameters.
There were no differences in blood pressure (BP) levels be-
tween HSD11B2 genotypes, but in a subgroup of 91 patients
that underwent diuretic therapy, CA repeat length was strongly
associated with the BP response to hydrochlorothiazide.
Conclusion. This study highlights the role of this HSD11B2
polymorphism in sodium handling and is consistent with a role
in the BP response to thiazide diuretics.
The nonselective mineralocorticoid receptor (MR) has
the same affinity in vitro for its physiologic substrate al-
dosterone and for the glucocorticoid cortisol [1, 2]. Be-
cause tissue concentrations of cortisol are much higher
than aldosterone, MR receptor specificity is mediated
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by the enzyme 11-beta hydroxysteroid dehydrogenase
type 2 (11bHSD2), which inactivates cortisol to corti-
sone [3]. The syndrome of apparent mineralocorticoid
excess (AME) is an autosomal-recessive form of salt-
sensitive hypertension caused by 11bHSD2 deficiency.
In this disorder, cortisol is not inactivated to cortisone
and, as a result, binds to the mineralocorticoid receptor
in target tissues, such as the distal nephron, thereby caus-
ing excessive sodium retention and potassium excretion.
The disease is caused by mutations in the 11bHSD2 gene
(HSD11B2), most of which markedly decrease or abolish
enzyme activity, and lead to an increased urinary excre-
tion of active cortisol (tetrahydrocortisol [THF]) to inac-
tive cortisone (tetrahydrocortisone [THE]) metabolites
[4].
Although AME is a rare disorder, it is possible that
mutations or polymorphisms with milder effects on
11bHSD2 activity could occur more frequently and be
a significant cause of hypertension in the general popu-
lation. In support of this hypothesis, heterozygous mu-
tations have been described in hypertensive patients in
whom the classic features of AME are absent [5], as
well as in patients with low renin hypertension [6]. Fur-
thermore, a mild impairment of 11bHSD2 activity has
been described in a subgroup of essential hypertensives
[7]. Some recent studies have investigated whether al-
terations in the HSD11B2 gene could play a role in the
pathogenesis of essential hypertension. A linkage study
using a microsatellite CA repeat marker in intron 1 of
the HSD11B2 gene and a silent polymorphism, G534A
(Glu178Glu), in exon 3, was performed in French hy-
pertensives, but did not show a significant association
of these polymorphisms with hypertension [8]. In con-
trast, in a study on Italian hypertensives, Agarwal et al
[9] found an association of the CA repeat microsatel-
lite allele length with salt-sensitive essential hypertension
[9]. In the same study, the authors showed that the ratio
of urinary-free cortisol/urinary-free cortisone, used as an
index of 11bHSD2 activity, was associated with shorter
CA repeat allele length; however, when minigenes,
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containing either “short” or “long” CA repeats, were
transfected into rabbit and human kidney cortical collect-
ing duct cells, the minigenes with short repeats were un-
expectedly expressed at higher levels compared to those
with long CA repeats [9]. The authors also showed that
the urinary-free cortisol/urinary-free cortisone ratio, was
lower in 33 salt-sensitive subjects compared to 34 salt-
resistant subjects; this association between allele length
and salt-sensitivity had been described previously in a
different study in young normotensive Germans [10].
To further address the role of the HSD11B2 gene in
essential hypertension, we studied 377 genetically ho-
mogenous essential hypertensives from North Sardinia.
Urinary tetrahydrocortisol (THF), allotetrahydrocortisol
(aTHF), tetrahydrocortisone (THE) were measured, and
their ratio [(THF+aTHF)/THE] was used as an index of
in vivo 11bHSD2 activity. The aims of our study were:
(1) to investigate if mutations in 11bHSD2 could account
for a mild reduction in enzyme activity in essential hyper-
tensive patients; (2) to investigate the effects of the CA
repeat and G534A polymorphism on blood pressure lev-
els and intermediate phenotypes (plasma renin activity,
PRA, (THF+aTHF)/THE); (3) to investigate the effects
of these polymorphisms on the blood pressure response
to thiazide diuretic therapy.
METHODS
Patients
Three hundred seventy-seven never-treated mild-to-
severe essential hypertensive patients were enrolled at
the Hypertension and Cardiovascular Prevention Cen-
ter, University of Sassari Medical School, Sassari, Italy,
after written informed consent and approval of study pro-
tocols by the local Ethics Committee. Patients were Sar-
dinians from at least six generations, born and resident in
domains of North Sardinia with a high degree of genetic
homogeneity, and were unrelated [11, 12]. In all patients
included in the study, the onset of hypertension had oc-
curred before the age of 60, as described previously for
another cohort [13]. Essential hypertension was defined
as systolic blood pressure (BP) ≥ 140 mm Hg and/or di-
astolic BP ≥ 90 mm Hg at the end of an eight-week obser-
vational period, during which seated BP and heart rate
were measured in the morning every two weeks (three
measurements per visit, by the same nurse in a quiet
room using an automated electronic device). Particular
care was taken in the examination of patients’ diet to ex-
clude the consumption of food containing glycyrrhetinic
acid, such as licorice and grapefruit [14]. In patients with
proteinuria in the morning urine sample, proteinuria was
quantified in the 24-hour urine collection before inclusion
in the study. Patients with more than 30 mg/day of protein
leaking were excluded. Secondary hypertension, as well
as chronic systemic diseases and clinically relevant acute
conditions, were excluded on clinical, laboratory, and
instrumental grounds. In particular, cholestasis was ex-
cluded by measurement of cglutamyltranspeptidase and
sonographic evaluation of the abdomen.
All patients were instructed to keep their sodium in-
take stable, and underwent a eight-week run-in period;
24-hour urinary sodium was measured at two weekly in-
tervals (accuracy of urine collection was checked by the
reproducibility of creatinine clearance), as well as seated
blood pressure (BP, the average of the last two readings
of four measurements taken at two-minute intervals by
the same nurse using an automated electronic device) and
body mass index (BMI). “Office” BP at the end of week
eight was taken as the reference value. Twenty-four–hour
urine and blood samples (at 8 a.m.) were also taken to
measure urinary electrolytes and aldosterone, as well as
upright PRA (upPRA) and recumbent PRA (recPRA).
We also measured plasma cortisol levels in those patients
with a (THF+aTHF)/THE ratio >2. A subgroup of 91 pa-
tients underwent monotherapy with hydrochlorothiazide
(25 mg/day) for eight weeks. The randomization was per-
formed using a table of random numbers without any
knowledge of patients’ genotype. After four and eight
weeks of therapy (weeks 12 and 16), BP levels were com-
pared to baseline levels (after the run-in period, week
eight).
Biochemical measurements
All measurements were performed on blood and urine
taken at the end of the run-in period (week eight). Uri-
nary THF, aTHF, and THE were measured as described
previously [7], and their ratio ((THF+aTHF)/THE) was
used as an index of 11bHSD2 activity [15]. The intra-assay
and interassay coefficients of variation were 7.8% and
10.3%, respectively. Electrolytes were measured by flame
photometry, whereas PRA and plasma aldosterone were
measured by radioimmunoassay as described [16, 17].
Plasma cortisol was measured using a RIA kit from Di-
agnostic Products Corporation (Los Angeles, CA, USA);
the normal range at 0800 hours was 10 to 20 lg/dL, with
intra- and interassay CVs of 4.1% and 5.0%, respectively.
Genotyping
Blood samples were drawn into EDTA-containing re-
ceptacles, and genomic DNA was extracted from pe-
ripheral blood leukocytes as described previously [17].
Patients with (THF+aTHF)/THE ratios ≥ 2 (N = 30)
were identified, and all five exons and intron-exon bound-
aries of the HSD11B2 gene were amplified by poly-
merase chain reaction (PCR) and sequenced on both
DNA strands as described elsewhere [18]; the promoter
region was not sequenced.
The G534A polymorphism located in exon 3 abolishes
an AluI restriction site in the presence of the A534 allele
[19]. This polymorphism was analyzed in all patients by
incubating 10 lL of the PCR product from the amplifica-
tion of exon 3 with 3U of AluI (New England BioLabs,
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Beverly, MA, USA) for 2 hours at 37◦C, before analysis of
digested products on 3.5% MetaPhor agarose (BioWhit-
taker Molecular Applications, Rockland, ME, USA) gels.
The CA microsatellite repeat located in intron 1 [20]
was analyzed in all patients by PCR amplification of a
DNA fragment comprising the CA repeat as described
previously [9]. A 6-FAM 5′-labeled sense primer was
used for PCR amplifications, and primer sequences, reac-
tion and cycling conditions were as described elsewhere
[9]. An aliquot of each PCR product (approximately
10 ng) was mixed with the internal size standard (Applied
Biosystems, Foster City, CA, USA) and used for Genes-
can microsatellite analysis on an ABI prism 3100 DNA
sequencer (PE Applied Biosystems). Data were gener-
ated using Genotyper software (Applied Biosystems).
Statistical analyses
SAS V8 software (SAS Institute, Inc., Cary, NC, USA)
was used for the statistical analyses. Data are expressed
as mean ± SD or median (minimum-maximum) when
appropriate. The normal distribution of parameters was
analyzed by the Kolmogorov-Smirnov test. We used the
Fisher exact test to analyze allele frequencies in the var-
ious patients’ groups.
Differences between two independent variables were
evaluated using a t test or the Mann-Whitney test when
appropriate. Analysis of variance between groups was
performed by analysis of variance (ANOVA) among vari-
ables, and the Bonferroni test was used to correct for
multiple comparison. A nonparametric ANOVA using a
Kruskal-Wallis test was used to evaluate differences be-
tween variables with nonparametric distribution.
The comparisons between variables were corrected for
the common confounding variables (BMI, age, and sex).
The Pearson product-moment or a Spearman’s correla-




There was a weak but significant correlation between
recPRA and the (THF+aTHF)/THE ratio (r = −0.09;
P = 0.04), whereas there was no statistically significant
correlation between upPRA and the (THF+aTHF)/THE
ratio (P = 0.18). All patients with a (THF+aTHF)/THE
ratio ≥2 displayed normal plasma cortisol levels at 8 a.m.
(13.2 ± 2.1 lg/dL).
Mutations in HSD11B2 gene
We identified 30 patients with an increased (THF+
aTHF)/THE ratio (≥2). To determine if mutations in
HSD11B2 could be responsible for the mild reduc-
tion of 11bHSD2 activity in these 30 patients, we se-
quenced the five exons and their intronic flanking regions.
Apart from the detection of two polymorphisms (G534A
Table 1. Clinical and biochemical parameters according to the
G534A polymorphism
Genotype AA+AG GG P value
N 35 342
Age years 48.3 ± 8.3 47.1 ± 9.7 0.51
BMI kg/m2 26.3 ± 2.7 27.3 ± 4.1 0.15
SBP mm Hg 160.6 ± 13.6 156.9 ± 14.2 0.14
DBP mm Hg 107.3 ± 7.3 105.2 ± 8.2 0.14
(THF+aTHF)/THEa 1.1 (0.42–2.41) 1.18 (0.27–3.10) 0.38
upALDO ng/dL 15.12 ± 6.19 13.39 ± 5.51 0.09
upPRA ng/mL × h−1a 1.6 (0.20–5.4) 1.6 (0.2–9.9) 0.59
recPRA ng/mL × h−1 0.93 ± 0.41 0.94 ± 0.59 0.92
UNa+ mEq/24h 138.74 ± 51.18 150.92 ± 51.72 0.99
UK+ mEq/24h 52.23 ± 15.93 52.23 ± 15.48 0.77
Abbreviations are: BMI, body mass index; SBP, DBP, sys-
tolic, diastolic blood pressure before treatment; (THF+aTHF)/THE,
(tetrahydrocortisol+allotetrahydrocortisol)/tetrahydrocortisone; upALDO,
plasma aldosterone levels in upright position; upPRA, plasma renin activity in
upright position; recPRA, plasma renin activity in recumbent position; UNA+,
urinary sodium levels; UK+, urinary potassium levels. Values are ± standard
deviation.
aData are expressed as median (minimum-maximum value). Differences
between groups were evaluated with nonparametric Mann-Whitney test.
[Glu178Glu] and C468A [Thr156Thr], detected in 3 and
2 patients, respectively, heterozygous in all cases), we did
not find any genetic polymorphisms or heterozygous or
homozygous mutations in any of the 30 patients analyzed.
G534A polymorphism
The allele frequencies were distributed in agreement
with the Hardy-Weinberg equilibrium.
Due to the low frequency of the A allele (only one
patient with the AA genotype), the GA and AA geno-
types were considered together. We found no difference
in blood pressure levels, (THF+aTHF)/THE ratio, and
the other parameters between patients with the GG com-
pared to those with the GA+AA genotypes (Table 1).
The number of patients in the GA subgroup was too
small to be informative for an analysis of the effect of the
G534A polymorphism on the diuretic response (9 GA vs.
82 GG).
CA repeat in intron 1
The length of the alleles in our population varied be-
tween 12 and 21 CA repeats, with 18 CA repeats being
the most frequent (Table 2). Fifty-five genotypes would
have been theoretically possible, 28 of which were present
in our population. Therefore, we used allele length (de-
fined as “long” or “short”) rather than genotype (abso-
lute number of CA repeats) for the analyses in order to
increase numbers within the subgroups. Alleles were sub-
divided into “long” or “short” depending on the length
of the CA repeat compared to the median (≤17 or >17
CA repeats), as in Agarwal et al [9]. When patients were
subdivided according to the genotype (considered as the
allele length: short/short = SS; short/long = SL; long/long
= LL), we found a statistically significant difference in the
634 Williams et al: HSD11B2, essential hypertension, and diuretic therapy












(THF+aTHF)/THE ratio between the genotypes (P =
0.04), but not for blood pressure levels or for the other
biochemical parameters studied (Table 3). Further, if the
short allele is considered dominant so that patients are
subdivided into two subgroups (SS+SL vs. LL), we found
a significantly higher (THF+aTHF)/THE ratio in SS+SL
patients compared to patients with the LL genotype (P =
0.02) (Fig. 1). The differences remain statistically sig-
nificant after correction for BMI, age, and sex (P =
0.01).
The (THF+aTHF)/THE ratio and the PRA levels in
each subject were correlated with the length of the shorter
and the longer allele carried by that subject (as if it
were a continuous variable); the shorter allele was sig-
nificantly related to the (THF+aTHF)/THE ratio (r =
−0.14; P = 0.006). We did not find a correlation of the
shorter allele with PRA levels, and the longer allele
was not related with either the (THF+aTHF)/THE ra-
tio or PRA levels. Further, we only considered alleles
carried by more than 30 patients; for the shorter allele,
we found a statistically significant trend for a decrease in
the (THF+aTHF)/THE ratio with an increasing number
of CA repeats (P = 0.01). In particular, for allele 16 the
ratio was 1.28 [0.56] (median [interquartile difference]),
allele 17 = 1.15 [0.58], and allele 18 = 1.11 [0.62]. We
also correlated the (THF+aTHF)/THE ratio with the six
most common genotypes (i.e., carried by more than 15 pa-
tients (16/17, 16/18, 17/17, 17/18, 18/18, 18/19). We found
a significant negative correlation between the genotypes
and the (THF+aTHF)/THE ratio (P = 0.02). Specifically,
for the genotype 16/17 the ratio was 1.22 [1.06]; genotype
16/18, ratio = 1.28 [0.43]; 17/17 = 1.18 [0.44]; 17/18 = 1.13
[0.63]; 18/18 = 1.09 [0.7]; 18/19 = 1.15 [0.61].
Response to diuretics
We used two different criteria to group patients ar-
bitrarily into responders (R) and nonresponders (NR)
depending on the reduction of the mean blood pressure
(MBP) after eight weeks of therapy. The median reduc-
tion of the MBP was 14 mm Hg: patients with a reduction
of the MBP ≥ 14 mm Hg were considered as MBPmed R,
and patients with a reduction of the MBP <14 mm Hg
as MBPmed NR. We also considered the median of the
percentage reduction of the MBP (MBPper R ≥ 10.9%,
MBPper NR <10.9%). We used the same criteria for SBP
(SBPmed R ≥ 16 mm Hg, SBPmed NR <16 mm Hg; SBPper
R ≥10.7%, SBPper NR <10.7%) and DBP (DBPmed R ≥
12 mm Hg, DBPmed NR <12 mm Hg; DBPper R ≥ 11.8%,
DBPper NR <11.8%).
By analysis of the genotype distribution (when geno-
types are considered as the actual number of the CA re-
peats) between R and NR for SBP, MBP, and DBP, we
found a significantly different distribution of the geno-
types (P < 0.01 for all). The allele distribution (consid-
ered as number of CA repeats) between N and NR was
significantly different for MBP (P = 0.038), but not for
SBP and DBP.
RecPRA was significantly correlated to percentage
SBP (r = −0.31, P = 0.002), MBP (r = −0.28, P = 0.007),
but not DBP (r = −0.22, P = 0.06) reduction, whereas
upPRA was only correlated to SBP reduction (r = −0.20,
P = 0.04). The (THF+aTHF)/THE ratio was correlated
to percent MBP reduction (r = 0.2; P = 0.049) and per-
cent DBP reduction (r = 0.22; P = 0.033) after diuretics
but not for the other parameters.
We also analyzed the data considering the BP response
after eight weeks of therapy as a continuous variable with
alleles dichotomized as “short” or “long” depending on
the length of the CA repeat compared to the median re-
peat length (17 CA repeats), where the short allele is
considered as dominant. This analysis demonstrated a sig-
nificantly higher SBP and MBP reduction under diuretic
therapy in patients with the SS+SL genotype (N = 56)
(−19.3 ± 16 and −15.7 ± 10 mm Hg) compared to those
with the LL genotype (N = 35) (−15.9 ± 9 and 13.1 ±
7 mm Hg, P < 0.001 and P = 0.01, respectively) (Fig. 2).
Further, patients with the SS+SL genotype displayed a
higher percentage SBP and MBP (−11.6 ± 9 and −12.6 ±
8%) reduction under diuretic therapy compared to pa-
tients with the LL genotype (−9.9 ± 5 and −10.7 ± 5%,
P < 0.001 and P = 0.01, respectively). There was no dif-
ference in the DBP and percentage of the DBP reduction
under diuretic therapy between the two groups (SS+SL:
−13.8 ± 8 mm Hg and −13.1 ± 8%; LL: −11.8 ± 7 mm
Hg and −11.3 ± 6, P = 0.2 for both comparisons)(Fig. 2).
We also compared the BP reduction after four weeks
of treatment in patients with SS+SL compared to pa-
tients with the LL genotype. This analysis demonstrated
a significantly higher SBP reduction in patients with the
SS+SL genotype (−19.3 ± 17.6 mm Hg) compared to
those with the LL genotype (−16.6 ± 11.1, P < 0.01).
Further, patients with the SS+SL genotype displayed a
higher percentage SBP (−11.5 ± 10%) reduction com-
pared to patients with the LL genotype (−10.3 ± 6.5%,
P < 0.01). There was no difference in the MBP and DBP
reduction between the two groups (SS+SL: −16.7 ± 11
and −15.6 ± 15.4 mm Hg; LL: −15.6 ± 8.9 and −14.4 ±
7.6 mm Hg, P = 0.08 and 0.3, respectively), despite a trend
for a reduction in the MBP.
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Table 3. Clinical and biochemical parameters according to the CA repeat allele length
Genotype SS SL LL P value
N (M/F) 51 (30/21) 186 (123/63) 140 (83/57)
Age years 46.8 ± 8.8 47.2 ± 10 47.4 ± 9.2 0.93
BMI kg/m2 26.6 ± 3.4 27.2 ± 4.1 27.4 ± 3.9 0.45
SBP mmHg 154 ± 13 158 ± 15 158 ± 14 0.18
DBP mmHg 104 ± 7 106 ± 8 105 ± 8 0.19
THF+aTHF/THEa 1.23 (0.5–2.6) 1.19 (0.4–3.1) 1.10 (0.3–2.5) 0.04
upALDO ng/dL 12.7 ± 6 14.2 ± 5.4 13 ± 5.6 0.10
recPRA ng/mL × h−1 0.96 ± 0.6 0.91 ± 0.58 0.97 ± 0.57 0.57
upPRA ng/mL × h−1 2.1 ± 1.5 1.9 ± 1.6 2.4 ± 3.7 0.37
UNa+ mEq/24h 145.7 ± 43.8 147.4 ± 51.2 154.4 ± 54.9 0.40
UK+ mEq/24h 50.7 ± 13.5 52.5 ± 14.9 52.4 ± 16.9 0.76
Abbreviations are: SS, homozygous for short allele (≤17 CA repeats); SL, heterozygous short-long; LL, homozygous for long allele (>17 CA
repeats); BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; THF+aTHF/THE, urinary cortisol metabolite ratio
(tetrahydrocortisol+allotetrahydrocortisol/tetrahydrocortisone); upALDO, upright aldosterone; upPRA, upright plasma renin activity; recPRA, recumbent
plasma renin activity; UNa+, urinary sodium; UK+, urinary potassium. Values are ± standard deviation.
aData are expressed as median (minimum-maximum value). Differences between groups were evaluated with nonparametric Kruskal-Wallis test. Differences were













Fig. 1. Effect of CA repeat allele length on urinary cortisol metabo-
lites ratio. Clustering box plot summarizing the differences in
(THF+aTHF)/THE levels after subdivision of patients according to
genotype. Median value is indicated by the thick line. Box plot and bar
indicate 75th and 95th percentile, respectively. SS, homozygous for short
allele (≤17 CA repeats); SL, heterozygous short-long; LL, homozygous
for long allele (>17 CA repeats). Differences remained significant after
correction for BMI, sex, and age (P=0.01), and after log-transformation
of the data to obtain a normal distribution (P = 0.01).
DISCUSSION
The present study is to our knowledge the largest study
investigating the role of the HSD11B2 gene in essential
hypertension. Further, it has been performed in a genet-
ically homogeneous cohort of never-treated individuals,
thereby reducing the number of confounders. The geo-
graphic location of Sardinia made this island substantially
isolated from commercial routes over the past centuries;
this led to the development of an isolated population from
an evolutionary point of view [21], similar to the Basque
and Finnish populations. Our cohort was composed of




























Fig. 2. Effect of CA repeat allele length (A) and percentage (B) on the
response to thiazide diuretic treatment. Differences in absolute blood
pressure levels after diuretic treatment and subdivision of patients ac-
cording to genotype: , SS+SL (N = 56); , LL (N = 35), where SS is
homozygous for short allele (≤17 CA repeats). SL, heterozygous short-
long; LL, homozygous for long allele (>17 CA repeats). Bars indicate
standard deviation. ∗P < 0.001; ∗∗P = 0.01.
avoiding effects on phenotypes from the previous use of
drugs.
In this large cohort we show an association of a
CA repeat polymorphism in the HSD11B2 gene with
11bHSD2 activity and of the (THF+aTHF)/THE ratio
with recPRA levels. We also show, in a subgroup of our
cohort, an association between this polymorphism and
the blood pressure response to thiazide diuretic therapy.
AME is an autosomal-recessive form of salt-sensitive
hypertension caused by 11bHSD2 deficiency. The clas-
sic form of the disease is very rare; however, mutations
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responsible for a mild impairment of 11bHSD2 func-
tion could be responsible for the increased blood pres-
sure in some patients with “essential hypertension.” This
hypothesis is supported by the finding of an increase in
cortisol/cortisone metabolites in a subgroup of patients
with essential hypertension and by the recent report that
patients with a phenotype indistinguishable from essen-
tial hypertensives carried mutations in HSD11B2 causing
reduced enzyme function [5, 6]. However, we did not find
any mutations in the HSD11B2 gene in our hypertensive
patients with increased (THF+aTHF)/THE ratios. The
slight reduction of 11bHSD2 activity in these patients is
therefore more likely due to a difference in HSD11B2
gene expression or in other post-transcriptional regula-
tory mechanisms, rather than to common mutations; the
possibility of an increased cortisol production was ruled
out by cortisol measurements. The present data are in
agreement with the hypothesis that any differences in to-
tal 11bHSD2 activity between hypertensive patients are
most probably the result of a reduction in the amount of
enzyme with an unaltered activity, rather than by a nor-
mal amount of enzyme with a decreased specific activity
and confirms the low prevalence of nonconservative mu-
tations found in another European population [22].
The CA repeat polymorphism in intron 1 of the
HSD11B2 gene was not associated with BP levels in our
genetically homogeneous North Sardinian population.
Therefore, in this case at least, it would appear that the
HSD11B2 gene does not play a major role in essential
hypertension. The CA repeat polymorphism was associ-
ated with the (THF+aTHF)/THE ratio, which in turn is
significantly related to recPRA values, suggesting a role
on sodium balance. This ratio has been demonstrated to
be the best indicator of 11bHSD2 activity in vivo, and
displays a lower intraindividual variability and a better
discrimination between salt-sensitive and salt-resistant
subjects compared to the ratio of the urinary free gluco-
corticoids (UFF/UFE) [15]. The G534A polymorphism
was not associated to any of the considered parameters.
The CA repeat polymorphism was strongly associated
with the blood pressure response to diuretic therapy with
hydrochlorothiazide: patients that carried at least one
“short” allele displayed a significantly higher blood pres-
sure reduction after diuretics compared to patients with
two “long” alleles. These findings are in agreement with
a previous study that found an association of the “short”
allele with salt sensitivity [9]. This observation could be
accounted for by a genetically determined mild reduc-
tion in HSD11B2 gene expression that induces miner-
alocorticoid receptor activation by cortisol leading to an
increase in sodium retention; these patients would be
more responsive to diuretic therapy compared to patients
in which this pathologic mechanism is not activated.
Among the biochemical variables, recPRA was better
than upPRA at predicting the BP response to diuretic
therapy and was related to the (THF+aTHF)/THE ra-
tio. The lack of a statistically significant correlation of
upPRA with BP response and the (THF+aTHF)/THE
ratio is likely due to the effect of posture on the sympa-
thetic system that may randomly affect renin secretion.
The association of the PRA status with the BP response
to therapy has already been described by others [23].
The (THF+aTHF)/THE ratio showed a weak correla-
tion with the BP response to diuretic therapy; the proba-
ble reason for the discrepancy between the effect of the
genotype and the effect of the (THF+aTHF)/THE ratio
on the BP response to diuretics could be that the ratio is
also determined by 11bHSD1 activity.
It may appear surprising that the short allele is dom-
inant because reduced function alleles are usually re-
cessive. However, there are in fact, some examples that
are coherent with our findings: (1) autosomal-dominant
pseudohypoaldosteronism type I is due to a heterozy-
gous loss-of-function mutation in the mineralocorticoid
receptor [24]; (2) a family with apparent mineralocor-
ticoid excess (AME) has been described where the
heterozygous state is associated with an abnormal phe-
notype (suppressed plasma renin activity and plasma
aldosterone level and a moderately elevated urinary cor-
tisol: cortisone metabolite ratio) [25]; (3) a patient with
mild low-renin hypertension has been described with a
homozygous mutation in the HSD11B2 gene. The pa-
tient did not demonstrate the typical features of AME
and biochemical analyses revealed a moderately elevated
cortisol to cortisone metabolite ratio. The conversion of
cortisol to cortisone was 58% compared with 0% to 6%
in typical patients with AME, whereas the normal con-
version is 90% to 95%.
These last two cases indicate that the complete func-
tion of both alleles seems to be necessary in order to have
a normal conversion of cortisol to cortisone. The model
of inheritance of mutations in the HSD11B2 gene may be
complex, and other factors can interfere with the pheno-
typic expression.
A limit of our study is that there is, to date, no demon-
stration of heritance of the cortisol to cortisone metabo-
lites ratio; however, there is a familial aggregation of
low-renin hypertension [26]. For this reason, the associ-
ation between the HSD11B2 polymorphism and the cor-
tisol to cortisone metabolite ratio and of the ratio with
low-renin hypertension can only be inferred indirectly,
but is nonetheless plausible.
In transfection experiments using minigenes of
HSD11B2 that carried either “short” or “long” alleles,
it was the minigenes carrying the short rather than the
long allele that resulted in increased levels of 11bHSD2
expression, which appears contradictory to the associa-
tion of the short CA repeat length with reduced 11bHSD2
activity [9]; however, considering other association stud-
ies in humans, the association between short alleles and
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salt sensitivity has been confirmed in genetically distinct
populations: German and Italian [9], blacks [27], and
in Sardinian patients in the present study. A possible
explanation for this paradox is that the CA repeat poly-
morphism in intron 1 is in genetic linkage disequilibrium
with another unknown polymorphism or regulatory se-
quence that has an effect on gene expression that over-
whelms any effect of the CA repeat itself [9, 28].
The results of the present study confirm that the CA
repeat polymorphism of the HSD11B2 gene might be
associated with sodium sensitivity [9, 10], a condition as-
sociated with an increased rate of cardiovascular compli-
cations [29]. However, our data reinforce and extend this
knowledge by showing an association of this genetic poly-
morphim with the blood pressure response to a thiazide
diuretic. Specifically, we show an association of “short”
CA repeat alleles with an increased (THF+aTHF)/THE
ratio, an index of 11bHSD2 activity, and with a greater
blood pressure reduction after diuretic therapy.
CONCLUSION
Thiazide diuretics are still considered the first-line ther-
apy in hypertension treatment; thus, the genetic basis for
the response to this type of drug is of particular inter-
est. The results of the present study contribute to an
understanding of the complex interaction between ge-
netic polymorphisms and the response to thiazide diuretic
treatment.
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